Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Comparison of natamycin and voriconazole for the treatment of fungal keratitis.

Prajna NV, Mascarenhas J, Krishnan T, Reddy PR, Prajna L, Srinivasan M, Vaitilingam CM, Hong KC, Lee SM, McLeod SD, Zegans ME, Porco TC, Lietman TM, Acharya NR.

Arch Ophthalmol. 2010 Jun;128(6):672-8. doi: 10.1001/archophthalmol.2010.102.

2.

The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole.

Prajna NV, Krishnan T, Mascarenhas J, Rajaraman R, Prajna L, Srinivasan M, Raghavan A, Oldenburg CE, Ray KJ, Zegans ME, McLeod SD, Porco TC, Acharya NR, Lietman TM; Mycotic Ulcer Treatment Trial Group..

JAMA Ophthalmol. 2013 Apr;131(4):422-9.

3.

Vision-Related Quality-of-Life Outcomes in the Mycotic Ulcer Treatment Trial I: A Randomized Clinical Trial.

Rose-Nussbaumer J, Prajna NV, Krishnan KT, Mascarenhas J, Rajaraman R, Srinivasan M, Raghavan A, Oldenburg CE, O'Brien KS, Ray KJ, McLeod SD, Porco TC, Lietman TM, Acharya NR, Keenan JD; Mycotic Ulcer Treatment Trial I Group..

JAMA Ophthalmol. 2015 Jun;133(6):642-6. doi: 10.1001/jamaophthalmol.2015.0319.

4.

Voriconazole versus natamycin as primary treatment in fungal corneal ulcers.

Arora R, Gupta D, Goyal J, Kaur R.

Clin Exp Ophthalmol. 2011 Jul;39(5):434-40. doi: 10.1111/j.1442-9071.2010.02473.x.

PMID:
21105974
5.

Association between in vitro susceptibility to natamycin and voriconazole and clinical outcomes in fungal keratitis.

Sun CQ, Lalitha P, Prajna NV, Karpagam R, Geetha M, O'Brien KS, Oldenburg CE, Ray KJ, McLeod SD, Acharya NR, Lietman TM; Mycotic Ulcer Treatment Trial Group..

Ophthalmology. 2014 Aug;121(8):1495-500.e1. doi: 10.1016/j.ophtha.2014.03.004.

6.

Organism, minimum inhibitory concentration, and outcome in a fungal corneal ulcer clinical trial.

Lalitha P, Prajna NV, Oldenburg CE, Srinivasan M, Krishnan T, Mascarenhas J, Vaitilingam CM, McLeod SD, Zegans ME, Porco TC, Acharya NR, Lietman TM.

Cornea. 2012 Jun;31(6):662-7. doi: 10.1097/ICO.0b013e31823f8ae0.

7.

Re-appraisal of topical 1% voriconazole and 5% natamycin in the treatment of fungal keratitis in a randomised trial.

Sharma S, Das S, Virdi A, Fernandes M, Sahu SK, Kumar Koday N, Ali MH, Garg P, Motukupally SR.

Br J Ophthalmol. 2015 Sep;99(9):1190-5. doi: 10.1136/bjophthalmol-2014-306485.

PMID:
25740805
8.

Comparative evaluation of topical versus intrastromal voriconazole as an adjunct to natamycin in recalcitrant fungal keratitis.

Sharma N, Chacko J, Velpandian T, Titiyal JS, Sinha R, Satpathy G, Tandon R, Vajpayee RB.

Ophthalmology. 2013 Apr;120(4):677-81. doi: 10.1016/j.ophtha.2012.09.023.

PMID:
23246119
9.

Expert prior elicitation and Bayesian analysis of the Mycotic Ulcer Treatment Trial I.

Sun CQ, Prajna NV, Krishnan T, Mascarenhas J, Rajaraman R, Srinivasan M, Raghavan A, O'Brien KS, Ray KJ, McLeod SD, Porco TC, Acharya NR, Lietman TM.

Invest Ophthalmol Vis Sci. 2013 Jun 14;54(6):4167-73. doi: 10.1167/iovs.13-11716.

10.

Medical interventions for fungal keratitis.

FlorCruz NV, Evans JR.

Cochrane Database Syst Rev. 2015 Apr 9;(4):CD004241. doi: 10.1002/14651858.CD004241.pub4. Review.

PMID:
25855311
11.

In vitro susceptibility of filamentous fungal isolates from a corneal ulcer clinical trial.

Lalitha P, Sun CQ, Prajna NV, Karpagam R, Geetha M, O'Brien KS, Cevallos V, McLeod SD, Acharya NR, Lietman TM; Mycotic Ulcer Treatment Trial Group..

Am J Ophthalmol. 2014 Feb;157(2):318-26. doi: 10.1016/j.ajo.2013.10.004.

12.

Voriconazole for fungal corneal ulcers.

Parchand S, Gupta A, Ram J, Gupta N, Chakrabarty A.

Ophthalmology. 2012 May;119(5):1083. doi: 10.1016/j.ophtha.2011.11.034. No abstract available.

PMID:
22551602
13.

Predictors of outcome in fungal keratitis.

Prajna NV, Krishnan T, Mascarenhas J, Srinivasan M, Oldenburg CE, Toutain-Kidd CM, Sy A, McLeod SD, Zegans ME, Acharya NR, Lietman TM, Porco TC.

Eye (Lond). 2012 Sep;26(9):1226-31. doi: 10.1038/eye.2012.99.

14.

Successful salvage treatment of Scedosporium apiospermum keratitis with topical voriconazole after failure of natamycin.

Al-Badriyeh D, Leung L, Davies GE, Stewart K, Kong D.

Ann Pharmacother. 2009 Jun;43(6):1139-42. doi: 10.1345/aph.1M008.

PMID:
19435962
15.

Management of tunnel fungal infection with voriconazole.

Jhanji V, Sharma N, Mannan R, Titiyal JS, Vajpayee RB.

J Cataract Refract Surg. 2007 May;33(5):915-7.

PMID:
17466872
16.

The successful medical treatment of a case of Paecilomyces lilacinus keratitis.

Wu PC, Lai CH, Tan HY, Ma DH, Hsiao CH.

Cornea. 2010 Mar;29(3):357-8. doi: 10.1097/ICO.0b013e3181af7626.

PMID:
20098311
17.
18.

Corneal Cross-linking as an Adjuvant Therapy in the Management of Recalcitrant Deep Stromal Fungal Keratitis: A Randomized Trial.

Uddaraju M, Mascarenhas J, Das MR, Radhakrishnan N, Keenan JD, Prajna L, Prajna VN.

Am J Ophthalmol. 2015 Jul;160(1):131-4.e5. doi: 10.1016/j.ajo.2015.03.024.

PMID:
25841317
19.

Corticosteroids for bacterial keratitis: the Steroids for Corneal Ulcers Trial (SCUT).

Srinivasan M, Mascarenhas J, Rajaraman R, Ravindran M, Lalitha P, Glidden DV, Ray KJ, Hong KC, Oldenburg CE, Lee SM, Zegans ME, McLeod SD, Lietman TM, Acharya NR; Steroids for Corneal Ulcers Trial Group..

Arch Ophthalmol. 2012 Feb;130(2):143-50. doi: 10.1001/archophthalmol.2011.315.

20.

The effects of intrastromal voriconazole injection and topical voriconazole in the treatment of recalcitrant Fusarium keratitis.

Siatiri H, Daneshgar F, Siatiri N, Khodabande A.

Cornea. 2011 Aug;30(8):872-5. doi: 10.1097/ICO.0b013e3182100993.

PMID:
21448063
Items per page

Supplemental Content

Support Center